The plasticity of prostate tumors is induced by their progression and therapeutic treatment, which is often presented by the conversion of AR-positive to AR-negative tumors and the lineage switch from adenocarcinomas to NE phenotype in advanced PCa [56], and as a result, it confers resistance of the advanced PCa to AR-targeting and other therapies. Here, AR is linked to prostate neoplasm.